Montefiore NEJM report with better explanation in
Post# of 148184
https://www.medscape.com/viewarticle/929585#vp_2
Note that the patients on ventilators who were being given either an IL-6 inhibitor (2 patients) or leronlimab (6 patients) had a combined survival rate of 50%. I believe reported rate of survival in the general population is only about 20% in New York for those placed on a ventilator. And, also, these are kidney transplant patients who are all on heavy immunosuppression. As already discussed here, the reduction in cytokines was already shown to be phenomenal after a few days but the effect on survival was unclear from the earlier information that we had.
We can now surmise the effect on survival.
Medscape is typically used by medical professionals for research information pertinent to current practice.